The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patient risk factors and pegfilgrastim use in cabazitaxel-treated prostate cancer pateints in an academic setting.
Marina Dusevic Kaymakcalan
No relevant relationships to disclose
Sherri Stuver
No relevant relationships to disclose
Christopher Sweeney
No relevant relationships to disclose
Toni K. Choueiri
No relevant relationships to disclose
Aymen Elfiky
No relevant relationships to disclose